BACKGROUND: Several studies have suggested that bisphosphonates have an antitumor effect. In the current study, the authors sought to evaluate whether the use of bisphosphonates increased the rate of pathological complete response (pCR) in patients with breast cancer. METHODS: The authors identified 1449 patients with breast cancer who were receiving taxane- and anthracycline-based neoadjuvant chemotherapy between 1995 and 2007 at The University of Texas MD Anderson Cancer Center. Patients who received bisphosphonates for osteopenia or osteoporosis while receiving chemotherapy were also identified. The primary outcome was the percentage of patients achieving a pCR. Groups were compared using the chi-square test. A multivariable logistic regression model was fit to examine the relation between the use of bisphosphonates and pCR. An exploratory survival analysis using the Kaplan-Meier method was performed; groups were compared using the log-rank test. RESULTS: Of the 1449 patients included, 39 (2.7%) received bisphosphonates. Those receiving bisphosphonates were older (P < .001) and less likely to be obese (P = .04). The pCR rate was 25.4% in the bisphosphonate group and 16% in the nonbisphosphonate group (P = .11). In the multivariable model, patients treated with bisphosphonates tended to have higher rates of pCR (odds ratio, 2.18; 95% confidence interval, 0.90-5.24); however, the difference was not found to be statistically significant. With a median follow-up of 55 months (range, 3 months-145 months), no differences in disease recurrence or survival were observed. CONCLUSIONS: The use of bisphosphonates at the time of neoadjuvant chemotherapy was not found to be associated with a statistically significant increase in the rates of pCR. The observed estimates suggest a positive effect; however, the small percentage of patients receiving bisphosphonates likely affected the power to detect a statistically significant difference.
BACKGROUND: Several studies have suggested that bisphosphonates have an antitumor effect. In the current study, the authors sought to evaluate whether the use of bisphosphonates increased the rate of pathological complete response (pCR) in patients with breast cancer. METHODS: The authors identified 1449 patients with breast cancer who were receiving taxane- and anthracycline-based neoadjuvant chemotherapy between 1995 and 2007 at The University of Texas MD Anderson Cancer Center. Patients who received bisphosphonates for osteopenia or osteoporosis while receiving chemotherapy were also identified. The primary outcome was the percentage of patients achieving a pCR. Groups were compared using the chi-square test. A multivariable logistic regression model was fit to examine the relation between the use of bisphosphonates and pCR. An exploratory survival analysis using the Kaplan-Meier method was performed; groups were compared using the log-rank test. RESULTS: Of the 1449 patients included, 39 (2.7%) received bisphosphonates. Those receiving bisphosphonates were older (P < .001) and less likely to be obese (P = .04). The pCR rate was 25.4% in the bisphosphonate group and 16% in the nonbisphosphonate group (P = .11). In the multivariable model, patients treated with bisphosphonates tended to have higher rates of pCR (odds ratio, 2.18; 95% confidence interval, 0.90-5.24); however, the difference was not found to be statistically significant. With a median follow-up of 55 months (range, 3 months-145 months), no differences in disease recurrence or survival were observed. CONCLUSIONS: The use of bisphosphonates at the time of neoadjuvant chemotherapy was not found to be associated with a statistically significant increase in the rates of pCR. The observed estimates suggest a positive effect; however, the small percentage of patients receiving bisphosphonates likely affected the power to detect a statistically significant difference.
Authors: Rowan T Chlebowski; Zhao Chen; Jane A Cauley; Garnet Anderson; Rebecca J Rodabough; Anne McTiernan; Dorothy S Lane; Joann E Manson; Linda Snetselaar; Shagufta Yasmeen; Mary Jo O'Sullivan; Monika Safford; Susan L Hendrix; Robert B Wallace Journal: J Clin Oncol Date: 2010-06-21 Impact factor: 44.544
Authors: Vered Stearns; Baljit Singh; Theodore Tsangaris; Jeanette G Crawford; Antonella Novielli; Mathew J Ellis; Claudine Isaacs; Marie Pennanen; Cecilia Tibery; Ahmad Farhad; Rebecca Slack; Daniel F Hayes Journal: Clin Cancer Res Date: 2003-01 Impact factor: 12.531
Authors: Trevor Powles; Sandy Paterson; John A Kanis; Eugene McCloskey; Sue Ashley; Alwynne Tidy; Kirsi Rosenqvist; Ian Smith; Lars Ottestad; Sandra Legault; Marjo Pajunen; Auli Nevantaus; Esa Männistö; Anne Suovuori; Sari Atula; Jaakko Nevalainen; Liisa Pylkkänen Journal: J Clin Oncol Date: 2002-08-01 Impact factor: 44.544
Authors: Marco Colleoni; Giuseppe Viale; David Zahrieh; Giancarlo Pruneri; Oreste Gentilini; Paolo Veronesi; Richard D Gelber; Giuseppe Curigliano; Rosalba Torrisi; Alberto Luini; Mattia Intra; Viviana Galimberti; Giuseppe Renne; Franco Nolè; Giulia Peruzzotti; Aron Goldhirsch Journal: Clin Cancer Res Date: 2004-10-01 Impact factor: 12.531
Authors: S Eva Singletary; Craig Allred; Pandora Ashley; Lawrence W Bassett; Donald Berry; Kirby I Bland; Patrick I Borgen; Gary M Clark; Stephen B Edge; Daniel F Hayes; Lorie L Hughes; Robert V P Hutter; Monica Morrow; David L Page; Abram Recht; Richard L Theriault; Ann Thor; Donald L Weaver; H Samuel Wieand; Frederick L Greene Journal: Surg Clin North Am Date: 2003-08 Impact factor: 2.741
Authors: Ayoub Charehbili; Duveken B Y Fontein; Judith R Kroep; Gerrit-Jan Liefers; Johannes W R Nortier; Cornelis J H van de Velde Journal: J Clin Med Date: 2013-10-16 Impact factor: 4.241
Authors: Young Kwang Chae; Erika N Brown; Xiudong Lei; Amal Melhem-Bertrandt; Sharon H Giordano; Jennifer K Litton; Gabriel N Hortobagyi; Ana M Gonzalez-Angulo; Mariana Chavez-Macgregor Journal: J Cancer Date: 2013-08-10 Impact factor: 4.207
Authors: Peter A Fasching; Sebastian M Jud; Maik Hauschild; Sherko Kümmel; Martin Schütte; Matthias Warm; Volker Hanf; Dieter Grab; Jutta Krocker; Elmar Stickeler; Rolf Kreienberg; Thomas Müller; Thorsten Kühn; Christopher Wolf; Steffen Kahlert; Stefan Paepke; Michael Berghorn; Mathias Muth; Monika Baier; Birgit Wackwitz; Rüdiger Schulz-Wendtland; Matthias W Beckmann; Michael P Lux Journal: BMC Cancer Date: 2014-02-05 Impact factor: 4.430